Egfr Gene Mutation clinical trials

Explore recruiting egfr gene mutation clinical trials.

Recruiting egfr gene mutation studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Egfr Gene Mutation trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Whole body HER3 quantification with radiolabelled Patritumab deruxtecan (HER3-DXd) PET/CT

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

(22615 SOHO-02) A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2-activating mutations

Italy, Spain, France, Denmark, Greece, Finland +12 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

First-line treatment with osimertinib in EGFR-mutated non-small cell lung cancer, coupled to extensive translational studies (The FIOL-study)

Norway, Lithuania, Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

A study to learn how BAY2927088 is taken up and handled by the body in healthy male participants

Netherlands

Human Pharmacology (Phase I)- Other EU CTIS Study details

An Open-label, Multicenter, Phase 1a/1b Study to Evaluate the Safety and Anti-tumor Activity of TT125-802 in Combination With Adagrasib, Osimertinib or Docetaxel in Patients with Advanced NSCLC

Spain

Human Pharmacology (Phase I)- Other EU CTIS Study details

(22752) A Phase 2 open-label basket study to evaluate the efficacy and safety of orally administered reversible tyrosine kinase inhibitor BAY 2927088 in participants with metastatic or unresectable solid tumors with HER2-activating mutations

Spain, Denmark, Italy, France

Therapeutic exploratory (Phase II) EU CTIS Study details

Egfr Gene Mutation trials by city

Egfr Gene Mutation in Toronto Egfr Gene Mutation in Vancouver Egfr Gene Mutation in Montreal Egfr Gene Mutation in Calgary Egfr Gene Mutation in Edmonton Egfr Gene Mutation in Ottawa Egfr Gene Mutation in Winnipeg Egfr Gene Mutation in Quebec City Egfr Gene Mutation in Hamilton Egfr Gene Mutation in Kitchener Egfr Gene Mutation in London Egfr Gene Mutation in Halifax Egfr Gene Mutation in New York Egfr Gene Mutation in Los Angeles Egfr Gene Mutation in Chicago Egfr Gene Mutation in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease